{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:19:18Z","timestamp":1787980758406,"version":"build-2784847793"},"reference-count":26,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb","award":["BMSQ13"],"award-info":[{"award-number":["BMSQ13"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Purpose: Pembrolizumab combined with chemotherapy is the standard of care for early-stage triple-negative breast cancer (TNBC) following KEYNOTE-522. However, real-world data on immune-related adverse events (irAEs) remain limited. We evaluated the incidence, severity, and clinical consequences of irAEs in a real-world cohort and compared outcomes with KEYNOTE-522. Methods: We conducted a retrospective cohort study of patients with stage II\u2013III TNBC treated according to the KEYNOTE-522 regimen at two Ontario cancer centres between June 2022 and May 2024. Data on irAEs, treatment discontinuation, and pathological complete response (pCR) were collected and contextualized against trial outcomes. Results: Among 79 patients, the pCR rate was higher than that reported in KEYNOTE-522 (77.2% vs. 64.8%). irAEs were documented in 51.9% of patients, compared with 33.5% in the trial. Permanent discontinuation due to irAEs occurred in 22.8% of patients, compared with 15.7% reported in KEYNOTE-522. Most discontinuations occurred during the neoadjuvant phase. Conclusions: Real-world patients experienced higher observed rates of low-grade irAEs and treatment discontinuation than reported in KEYNOTE-522; however, differences in study design limit direct comparison. These findings highlight the need for optimized toxicity management and further study of the impact of treatment duration on long-term outcomes.<\/jats:p>","DOI":"10.3390\/curroncol33090513","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:47:13Z","timestamp":1787849233000},"page":"513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"33","author":[{"given":"Emmanuel Joran","family":"Boujeke","sequence":"first","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8795-607X","authenticated-orcid":false,"given":"Aaron","family":"Catalan","sequence":"additional","affiliation":[{"name":"Windsor Regional Hospital, Windsor, ON N82 2X3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurice","family":"Arayan","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred Patrick","family":"Mina","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"},{"name":"Windsor Regional Hospital, Windsor, ON N82 2X3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Edward","family":"James-McDonald","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasna","family":"Gupta","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"},{"name":"Windsor Regional Hospital, Windsor, ON N82 2X3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"},{"name":"Windsor Regional Hospital, Windsor, ON N82 2X3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-2861","authenticated-orcid":false,"given":"Abdullah","family":"Nasser","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"},{"name":"Windsor Regional Hospital, Windsor, ON N82 2X3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepro","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"},{"name":"Windsor Regional Hospital, Windsor, ON N82 2X3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7741-2199","authenticated-orcid":false,"given":"Muriel","family":"Brackstone","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"},{"name":"London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mathews","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-2088","authenticated-orcid":false,"given":"Caroline","family":"Hamm","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"},{"name":"Windsor Regional Hospital, Windsor, ON N82 2X3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-Negative Breast Cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An Overview of Triple-Negative Breast Cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in Breast Cancer Survival by Molecular Subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive Analysis of Estrogen Receptor (ER)-negative, Progesterone Receptor (PR)-negative, and HER2-negative Invasive Breast Cancer, the So-called Triple-negative Phenotype: A Population-based Study from the California Cancer Registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-World Evidence\u2014What Is It and What Can It Tell Us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41698-021-00223-x","article-title":"Real-World Data Analyses Unveiled the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors across Cancer Types","volume":"5","author":"Wang","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/OP.24.00371","article-title":"Real-World Immune-Related Adverse Events in Patients with Early Triple-Negative Breast Cancer Who Received Pembrolizumab","volume":"21","author":"Jayan","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: Building an International Community of Software Platform Partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1245\/s10434-024-16390-7","article-title":"Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer","volume":"32","author":"Connors","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-025-07758-8","article-title":"Adverse Events in Patients Treated with Neoadjuvant Chemo\/Immunotherapy for Triple Negative Breast Cancer: Results from Seven Academic Medical Centers","volume":"213","author":"Hsu","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104473","DOI":"10.1016\/j.breast.2025.104473","article-title":"Immune-Related Adverse Events among Patients with Early-Stage Triple-Negative Breast Cancer Treated with Pembrolizumab plus Chemotherapy: Real-World Data from the Neo-Real\/GBECAM 0123 Study","volume":"83","author":"Andrade","year":"2025","journal-title":"Breast Edinb. Scotl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-Resident Memory and Circulating T Cells Are Early Responders to Pre-Surgical Cancer Immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e009722","DOI":"10.1136\/jitc-2024-009722","article-title":"Immune Checkpoint Blockade: Timing Is Everything","volume":"12","author":"Sinicrope","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13063-025-08726-9","article-title":"A Phase II, Randomized, Open-Labeled Study to Evaluate Low-Dose Pembrolizumab in Addition to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)","volume":"26","author":"Arora","year":"2025","journal-title":"Trials"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100664","DOI":"10.1016\/j.esmorw.2025.100664","article-title":"UK Real-World Evidence on Pembrolizumab and Neoadjuvant Chemotherapy for Early-Stage Triple-Negative Breast Cancer","volume":"11","author":"McKeon","year":"2026","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100061","DOI":"10.1016\/j.esmorw.2024.100061","article-title":"Real-World Safety and Effectiveness of Neoadjuvant Chemotherapy Combination with Pembrolizumab in Triple-Negative Breast Cancer","volume":"5","author":"Rached","year":"2024","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.jid.2022.04.020","article-title":"Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study","volume":"142","author":"Le","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and Risk Factors for the Development of Cutaneous Toxicities in Patients Treated with Immune-Checkpoint Inhibitors: A United States Population-Level Analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-021-06480-5","article-title":"Immunotherapy Toxicity: Identification and Management","volume":"192","author":"Gumusay","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_23","first-page":"44896","article-title":"Real-World Outcome of Neoadjuvant Therapy with or without Pembrolizumab for Triple-Negative Breast Cancer","volume":"65","author":"Maunu","year":"2026","journal-title":"Acta Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2275846","DOI":"10.1080\/2162402X.2023.2275846","article-title":"Emergence of Immune-Related Adverse Events Correlates with Pathological Complete Response in Patients Receiving Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"12","author":"Marhold","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bischoff, H., Somme, L., and Petit, T. (2025). Optimizing Post-Neoadjuvant Treatment in Early Triple-Negative Breast Cancer. Cancers, 17.","DOI":"10.3390\/cancers17203288"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO-24-01739","article-title":"Novel Postneoadjuvant Prognostic Breast Cancer Staging System","volume":"43","author":"Winchester","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/513\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:51:06Z","timestamp":1787979066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090513"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090513","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}